bpc-157 histamine intolerance The Role of Prescriptive Peptides for Chronic GI and Autoimmune Conditions MCAS or histamine intolerance can

Patients with severe hepatic or renal impairment may require special consideration, though specific dosing guidelines for these populations have not been established

The peptide's effects on growth factor signaling and vascular function may theoretically interact with certain medications affecting these pathways

No human clinical trials exist for BPC-157 in GERD or any other indication

Critics argue that the FDA's caution could restrict access to a potentially beneficial compound, advocating for a more balanced approach that considers BPC-157's therapeutic potential

Ethics statement The studies involving humans were approved by Research Ethics Committee, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan